FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Ianchulev Tsontcho 2. Issuer Name and Ticker or Trading Symbol EYENOVIA, INC. [ EYEN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)         (First)         (Middle)
C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400
3. Date of Earliest Transaction (MM/DD/YYYY)
11/20/2020
(Street)
NEW YORK, NY 10017
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $.0001  11/20/2020    J(1)    453333  D $0.00  0  I  By PME Investor Services Eyenovia, LLC (2)
Common Stock, par value $.0001                 508679  D   
Common Stock, par value $.0001                 606667  I  By Private Medical Equity, Inc. (2)
Common Stock, par value $.0001                 6000  I  By The Meliora Trust (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class A Warrant  $2.27 (3)                 3/24/2020  3/24/2021  Common Stock  41216 (4)   41216 (4) D   
Class B Warrant  $2.724 (3)                 3/24/2020  3/24/2025  Common Stock  61823 (4)   61823 (4) D   
Stock Option (right to buy)  $1.95                   (5) 7/7/2027  Common Stock  267370    267370  D   
Stock Option (right to buy)  $6.20                   (6) 7/24/2028  Common Stock  124210    124210  D   
Stock Option (right to buy)  $3.11                   (7) 8/16/2029  Common Stock  183703    183703  D   
Stock Option (right to buy)  $2.72                   (8) 6/2/2030  Common Stock  285255    285255  D   
Stock Option (right to buy)  $1.24                  3/23/2015  3/23/2025  Common Stock  140000    140000  I  By Private Medical Equity, Inc. (2)

Explanation of Responses:
(1)  On November 20, 2020, PME Investor Services Eyenovia, LLC, of which the reporting person is a manager, distributed its holdings of the Issuer's common stock in-kind and on a pro rata basis to its members.
(2)  The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
(3)  The exercise price per share of the Issuer's common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events.
(4)  The number of shares of Issuer common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events.
(5)  The option became exercisable as to 11,140 shares on August 7, 2017 and became exercisable in equal 11,140 share amounts on each of the 35 one-month anniversaries thereafter.
(6)  This option is fully vested.
(7)  One-third of the option became exercisable on August 16, 2020 and the remaining shares underlying the option become exercisable in equal increments on each of the 24 one-month anniversaries thereafter.
(8)  One-third of this option becomes exercisable on June 3, 2021 and the remaining shares underlying the option become exercisable in equal increments on each of the 24 one-month anniversaries thereafter.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ianchulev Tsontcho
C/O EYENOVIA, INC.
295 MADISON AVENUE, SUITE 2400
NEW YORK, NY 10017
X
Chief Executive Officer

Signatures
/s/ S. Halle Vakani, Attorney-in-Fact 11/24/2020
**Signature of Reporting Person Date